One of south Donegal’s oldest and well-known pubs has been placed on the market, it has emerged. Biddy’s Bar of Glencolmcille, which was built over 200 years ago, has been a popular well-loved watering hole for tourists who visit the Gaeltacht village. However, after years of falling into disrepair, the current owners have now took the decision to sell the pub.The folk village is on the Atlantic coast west of Donegal Town in the north-west of Ireland. It consists of several small cottages in the Gaeltacht.It was built and maintained by the local people and it is one of Ireland’s best living-history museums.Biddy’s Bar of GlencolmcilleThe cottages are exact replicas of those used by local people in the 18th, 19th and 20th centuries and fitted with the furniture of this period.The property can be found listed on daft.ie: “We are delighted to offer for sale, this former traditional public house known locally as Biddy’s Bar of Glencolmcille. The property comprises of a two-storey detached building consisting of a bar and lounge that extends to approximately 216 sq.m / 2,325 sq.ft in area. “The ground floor comprises of a bar with direct access onto the main street and is connected to a separate lounge.“The first-floor accommodation positioned over the ground floor also consists of a bar and lounge and features a double-height vaulted ceiling with exposed stone walls.“The remaining accommodation comprises of a sizable lean-to consisting an open-span bar with independent access.”Picture Special: Well known south Donegal pub for sale for €125,000 was last modified: October 31st, 2019 by Staff WriterShare this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window)
Click HERE if you’re having trouble viewing the gallery on your mobile device.NEW YORK — The A’s making history by becoming the first club to ever try “bullpenning” in the playoffs isn’t even the craziest part about the whole thing. That distinction belongs to the man actually starting the game.A’s reliever Liam Hendriks will open up Wednesday night’s wild-card game, opposing Yankees starter Luis Severino.Tasked with getting through a clean first inning at Yankee Stadium is the same Hendriks …
At any time, courts could rule on whether funding of embryonic stem cell research can continue or must be halted. Whichever way a decision is rendered, whether by Judge Lamberth on the legality of the NIH guidelines, or by the Court of Appeals for DC, the issue will probably wind up before the Supreme Court. Passions run high on both sides. A crusader for adult stem cells, profiled in Nature this past week,1 was surprised by how many scientists support her antagonism to the use of human embryos for research. More on that later; first, some news highlights:Cooling the flame: Science Daily told how adult stem cell therapy can reduce inflammatory damage from stroke. “We are seeing a paradigm shift in the way some types of stem cells may enhance recovery from stroke,” an excited researcher at the University of Texas said. The adult stem cell therapy appears to dampen inflammation involving the spleen. This new treatment holds promise to “improve clinical care, reduce long-term health care costs, and improve the quality of life for millions of people.”iPS momentum: PhysOrg reported that researchers at Harvard and Columbia have demonstrated that “many iPS cells are the equal of hESCs in creating human motor neurons, the cells destroyed in a number of neurological diseases, including Parkinson’s.” Induced pluripotent stem cells (iPS) are a form of adult stem cell that does not involve the destruction of embryos (11/20/2007), as in human embryonic stem cells (hESC). The article says that iPS cells meet the “gold standard” of pluripotency. In addition, new methods are speeding the tests for pluripotency of iPS cells.Hearty iPS: Another story on PhysOrg highlighted research at Stanford that shows iPS cells can generate beating heart cells that carry a genetic defect under study, allowing “for the first time to examine and characterize the disorder at the cellular level.”ESC economics: PhysOrg also discussed the current disarray of patent laws surrounding stem cell lines, data, and treatments. Some scientists warn of a potential “stifling effect of widespread patenting in stem cell field.” Bioethicist Debra Matthews (Johns Hopkins) said, “Pervasive taking of intellectual property rights has resulted in a complex and confusing patchwork of ownership and control in the field of stem cell science.” Although the article was unclear whether the dispute includes adult stem cell research, it mentioned one recommendation being “a centralized portal for access to existing databases, such as the UK Stem Cell Bank and the Human Embryonic Stem Cell Registry.”Mixed bag: Another article on PhysOrg discussed the new Massachusetts Medical School Human Stem Cell Bank, which opened with seven high-quality stem cell lines (5 embryonic, 2 iPS, with more to follow), and how they are being preserved in liquid nitrogen and made available to researchers around the world. The article mixed these two sources of stem cells with no mention of ethics: e.g., “The Registry includes information on the derivation, availability and characteristics for more than 1,200 hESC and iPS cell lines developed in over 22 different countries, including more than 200 cell lines with genetic disorders.”Sex cells: Parthenogenetic stem cells are taken from reproductive cells (03/12/2005). Lacking the full complement of chromosome pairs, they might contain a good or bad copy of a gene implicated in a disease like tuberous sclerosis or Huntington’s disease. Science Daily discussed how work at Nationwide Children’s Hospital is constructing good embryonic stem cells from parthenogenetic cells. “These single-parent/patient-derived embryonic stem cells can theoretically be used for correction of a diverse number of diseases that occur when one copy of the gene is abnormal,” a research at the hospital said.“The Crusader”With the decision by Judge Lamberth last September prohibiting federal funding of embryonic stem cell research (09/03/2010) still under an injunction (09/26/2010), researchers and bioethicists are waiting to see what the next court ruling will bring. Nature published the story of “The Crusader,” Theresa Deisher, one of the two remaining plaintiffs who won in the September case.1 Reporter Meredith Wadman presented Deisher in a fairly positive light as an intelligent, confident, persistent, self-sacrificing, hard-working PhD in cell biology, respected by her enemies, a Roman Catholic who “once shunned religion for science” but regained her faith when realizing that fetuses were not just “clumps of cells,” but human beings (cf. 11/07/2002). Deisher’s politics in college were “very left-wing,” after she ditched her mother’s religious faith. “I was in science, and science was much more interesting than religion,” she said. “I encouraged a couple of friends to have abortions.” Her return to faith came by degrees: first, the sight of an adult cadaver preserved in formalin made her realize that a fetus preserved in a jar only looks “alien” because of the preservation method. Second, she encountered first-hand the passions of those bent on researching human embryos; “And the vehemence with which colleagues resisted ‘made me open my eyes’, Deisher says, to the very real – and, she says, unscientific – passions that can infect defenders of scientific orthodoxy,” Wadman wrote. “Science, she reasoned, was not so objective after all.” Third, Deisher’s growing antipathy to embryonic stem cell research got an emotional kick when speaking to Republican state lawmakers in Washington state in 2007. “One of the other speakers was a mother who had adopted a frozen embryo from a fertility clinic,” Wadman continued. “The resulting child, a girl then four years old, stood beside her.” Deisher sold her house and used her retirement savings to start an institute for the advancement of adult stem cell therapies. She is not, thereby, antagonizing scientists by opposing them through the political process; when asked, she reluctantly signed on as a plaintiff in the lawsuit that resulted in Lamberth’s ruling: “It is frightening to speak out,” she said; “I don’t care for the notoriety.” Instead, her AVM Biotechnology company seeks to provide positive alternatives: “The company’s mission, in part, is to eliminate the need for embryonic-stem-cell therapies and enable adult-stem-cell companies to succeed by developing, for instance, drugs that promote stem-cell retention in target organs,” It is also working on alternatives to vaccines currently produced using cell lines derived from fetuses that had been aborted decades ago.” Unlike the institutes in California that have $3 billion in taxpayer-approved bonds at their disposal, Deisher runs her company in a dormitory with five unpaid staff. A lot rides on the court’s next move. If the court agrees with Deisher, Wadman ended, “it will shut down hundreds of human-embryonic-stem-cell experiments once more – possibly for good.” One of the most interesting things Deisher learned from the lawsuit – indeed, the “biggest lesson,” Wadman called it – was, in Deisher’s words, “how many scientists are against [human-embryonic-stem-cell research]. I did not know that. I did not expect the level of support and encouragement that I have received.”1. Meredith Wadman, “The Crusader,” Nature 470, 156-159 (Feb 9, 2011) | doi:10.1038/470156a.That Nature would print this story about Deisher is an encouraging sign that the momentum may be turning away from embryonic stem cell research. Nature used to wield its editorial pen against the opponents the way it does against creationists, calling them ignorant moralists standing in the way of progress (02/11/2005, 09/27/2004). Dr. Tracy Deisher certainly does not fit that description, nor does Dr. James Sherley, an adult stem cell researcher at Boston Biomedical Research Institute, the other remaining plaintiff in the lawsuit. For sure, Wadman snuck in enough jibes about Deisher to titillate Nature’s leftist readers (calling her a “bundle of contradictions,” pointing out that she never applied for a NIH grant, pointing out that she studies the “pernicious” and “disproven” hypothesis that autism might be triggered by vaccines, quoting people who call her “polarizing,” remarking in a callout box that “she’s kind of the Sarah Palin of stem cells,”), but she gave Deisher a lot of room to respond, too. What was not said may be more telling. Wadman did not point out any benefits of embryonic stem cells over adult stem cells. She did not quote any leading ES researchers making a good case for cutting up embryos. And she did not even attempt to defend ES research on ethical grounds. Instead, she gave Deisher space to make two striking blows: (1) that many scientists are opposed to human embryonic stem cell research, and (2) that hESC researchers are not driven primarily by concern for the sick. Researchers prefer to work on ES cells because they are convenient, Deisher argued; their science “is not about helping patients and it’s not about advancing the common good.” Instead, she argued, “There is no commercial, clinical or research utility in working with human embryonic stem cells.” That anecdote about the four-year-old girl born from a frozen embryo added emotional clout. Here was a darling human being – obviously a great deal more than a clump of cells. These are signs that embryonic stem cell research is losing its hype-driven public mandate (cf. 01/02/2011). After all the promises, it has produced no cures (while adult stem cell research is on a roll; see 11/18/2010 starting from initial promise in 01/24/2002). It is superfluous, now that iPS technology is its equal, without the ethical qualms. Its credibility has been marred by fraud (12/16/2005), while others worry about future abuses (10/21/2004; cf. 04/22/2004 and 07/30/2001 on eugenics). Opponents within the scientific community are becoming more bold. And it is hanging by a thread, waiting for the next court ruling that might end its federal funding for good (double entendre intentional). But why should it get federal funding in the first place? If the promises were credible, commercial and charitable support would be overwhelming. That ES researchers have to lean on the government dole is a sign it is not commercially viable. Is this subject relevant for Creation-Evolution Headlines? Maybe not directly, but one’s view of the origin of life and humanity has direct bearing on ethics. The stem cell controversy of the past decade has been a direct outgrowth of competing views on the significance of human life. If an embryo is “just a clump of cells,” then playing with those clumps because of their convenience or the temptation of a Nobel prize has no ethical consequences. But if human life was created by God, it never loses its sanctity from conception to burial. It will affect how we view a fetus in a jar, a plasticized body in an exhibit, an Alzheimer’s patient in a nursing home, a woman considering an abortion, the direction of scientific research. It’s where the rubber of worldview meets the road of scientific practice.(Visited 40 times, 1 visits today)FacebookTwitterPinterestSave分享0
Kuala Lumpur-based AirAsia is having another tilt at a joint venture in Vietnam that will pit it against the well-established operations of Jetstar Pacific and VIetJet. Wholly-owned AirAsia subsidiary AirAsia Investment Limited signed an agreement on March 30 week with Gumin Company Limited, the Hai Au Aviation Joint Stock Company and their owner Tran Trong Kien to establish a budget carrier in the fast-growing market.The budget carrier will own 30 per cent of the joint venture which plans to start flying in 2018, subject to Vietnam’s often difficult regulatory process.Vietnam’s aviation market has been growing at a healthy clip and Bloomberg estimates the growth is three times the rate in other Southeast Asian countries.Government statistics show there were 52.2 million air travellers in Vietnam in 2016, an increase of 29 per cent year-on-year, with 28 million flying domestically. The International Air Transport Association has predicted there will be 112 million new passengers in Vietnam over the next two decades.This is AirAsia’s third attempt to get a foothold in Vietnam as part of its strategy to establish an Asian network and the CAPA Centre for Aviation believes being late to the market will make the job more difficult. “ AirAsia was initially partnered with VietJet Air but the partnership was dissolved prior to VietJet commencing operations in late 2011,’’ CAPA said.“The market has since more than doubled in size, and Vietnam has emerged as Southeast Asia’s fastest growing market. “While there is further growth potential, the LCC incumbents VietJet and Jetstar Pacific have first mover advantage, and infrastructure constraints could make it difficult for any new entrant to establish a significant presence.”AirAsia will also need to overcome regulatory hurdles.”Known for publicity stunts involving bikini-clad girls, VietJet launched in 2011 as Vietnam’s first privately owned “new age” carrier and publicly listed earlier this year.It operates almost 40 Airbus A320 and A321 aircraft to about 60 domestic and international destinations with ports in Thailand, Singapore, South Korea, Taiwan, Malaysia, China, Japan, Hong Kong and Myanmar. It hopes to have a fleet of 200 aircraft by 2023 and last year placed an order with Boeing for 100 737 MAX jets with a list price of $US11.3 billion.Jetstar Pacific launched in 2008 and now flies to 16 domestic and international destinations with a fleet of 10 Airbus A320 aircraft. It has plans to expand its fleet to 30 A320s.Australia’s Jetstar Group owns 30 per cent of the airline while Vietnam Airlines, which is also a codeshare partner with Jetstar, owns the remainder.Jetstar’s Australian long-haul operations will move in May to reconnect with its sister airline when it resumes flights to Ho Chi Minh City.Starting May 10, Jetstar will operate Boeing 787 Dreamliner services three times weekly from Melbourne and four times weekly from Sydney.Jetstar Group chief executive Jayne Hrdlicka in January described Vietnam as one of the fastest growing holiday destinations in South East Asia.“Vietnam has the potential to become as popular as Bali or Thailand for Australian travellers,” Hrdlicka said. “Vietnam is well known for its rich culture, vibrant cities, beaches and cuisine, and travellers can take advantage of the wide range of experiences the region has to offer.“We expect our low fares and direct flights will generate even more demand for holidays to Vietnam.’’Jetstar International first flew to Vietnam from Australia a decade ago.
Impossible to beat. Impossible to subdue.What does an indomitable mindset mean for salespeople? Why is it important? How do you develop one?The foundation of an indomitable mindset is an indomitable belief structure. As you go through life, you pick up dozens and dozens of infections. You don’t even know you’re picking them up, but these infections determine what kind of results you produce and what level of success you achieve.Maybe you were infected with the belief that the obstacles to better performance are external. It’s not you, it’s the economy. It’s not you, it’s your sales manager. It’s not you, it’s your competitors’ willingness to sell on price alone. These are very common infections, and they weaken your mindset.The wonderful thing about beliefs is that they are infections you can choose for yourself. You can choose to believe that the obstacles to better performance are all internal. You can believe that you are responsible for everything that happens to you. It’s not the economy, it’s the fact that you haven’t adjusted your approach to take advantage of new economic realities. It’s not your sales manager, it’s the fact that you aren’t selling him or her like you sell to your prospective clients. It’s not your competitor’s willingness to sell on price that causes you to lose opportunities, it’s your inability to justify the delta between your price and theirs.Your beliefs drive your behaviors and your behaviors determine your results. Without a powerful underlying belief system, you cannot have an indomitable mindset.In my first book, The Only Sales Guide You’ll Ever Need, I identified nine attributes that make for a powerful mindset. Those attributes include self-discipline, optimism, caring, competitiveness, resourcefulness, initiative, persistence, communication, and accountability. These attributes are all part of what makes up an indomitable mindset.If you want to create an indomitable mindset of your own, study people that already have one. Adopt their beliefs as your own, especially the beliefs that make you uncomfortable. In short order, you’ll find yourself taking new actions, and producing new results. You’ll also find yourself with an indomitable mindset.
Self-medication is not new to India. A 2015 survey conducted by Lybrate among 20,000 people across 10 cities showed that 52% of people practised self-medication. But the country lacks a well-defined regulation for over the counter (OTC) medicines, important for patient safety. The government is in the process of finalising an OTC drug policy, which may bring more clarity on the drugs that a wider population can access. The Organisation of Pharmaceutical Producers of India (OPPI), a body of multinational drug companies, has worked with the government over the past one year by providing inputs to the draft of the OTC policy.The Hindu spoke to OPPI president Annaswamy Vaidheesh about the need for such guidelines and the changes they will bring about in healthcare.What role did OPPI play in creating the OTC policy draft?We brought experts together to help develop the guidelines. We also invited companies like Cipla, Glenmark, Sun Pharma and others who are not members of OPPI, but their inputs were valuable. Additionally, we got international experts to bring in perspective. The government has hailed the inputs and is seriously considering taking them forward. We have looked at the best practices in various economies and highlighted what we can take from them, the kind of drugs that should be included in the OTC list and the ones that should not.How will an OTC policy help?First of all, when you widen access to OTC drugs, it automatically releases the government’s time and resources, which can be focussed on drugs that need to be stringently prescribed. We are saying that drugs that are known to have negligible side effects and don’t require much explanation can be classified as OTC so that access to them becomes easy and wide. These drugs can be made easily accessible in small towns as well. The idea is to make sure that the right product rests in the right place. Society has learnt that OTC medicines are those that don’t have major side effects but help improve health. Many countries have brought more products under the OTC category to focus on drugs that need to be strictly regulated.We also face the threat of antibiotics resistance. Will bringing more drugs under the OTC category lead to overuse or misuse? An antibiotic is a drug meant to treat a bacterial infection. But people who have viral infections, fever and so on are taking antibiotics, causing the resistance. However, when drugs for common viral infections, sore throat, acidity, indigestion, nausea, vomiting, stomach pain, injury, cuts, wounds, burns, acne etc are made available under OTC, people will get access to the right medication. Many people are using such drugs without prescription anyway. But an OTC policy will improve access to drugs that are okay to be sold as OTC and restrict access to other drugs. Besides antibiotic resistance, steroid use is also a big problem. There are people who use steroid creams for skin whitening. But we are working with the government to spread awareness about the responsible use of antibiotics and steroids.What stage is the policy in?The submission has gone; we have crossed three-fourths of the passage. The government may take six months or a year. It is in the process of finetuning it and converting it into a legislation.